Canadian clinical-stage biopharmaceutical company BioVaxys Technology Corp (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) announced on Thursday the appointment of Brittany Davison, CPA, CA as its new business advisor.
Davison, a chartered professional accountant, is the owner of Davison CPA Consulting Inc of Halifax, Nova Scotia. She previously served as chief accounting officer and acting chief financial officer at IMV Inc and as audit senior with Grant Thornton LLP.
Kenneth Kovan, BioVaxys president & chief operating officer, said: "We are delighted to have engaged Brittany who is a significant addition to our team where she will assist with further knowledge transfer associated with the former IMV Inc assets, support investor relations, business development targeting and outreach, and facilitate sources of private funding, government funding and Scientific Research and Experimental Development (SR&ED) tax incentives."
Merck announces Phase 3 trials for once-monthly oral HIV prevention pill MK-8527
GSK announces submission of RSV vaccine Arexvy for FDA review
AstraZeneca's Baxdrostat meets all endpoints in pivotal Phase III hypertension trial
IGI and AbbVie enter global licensing agreement for ISB 2001
REGENXBIO reports RGX-202 preclinical results in Duchenne Muscular Dystrophy
MetaVia doses first patient in 48 mg MAD cohort of DA-1726 Phase 1 trial
GenScript Biotech awarded EcoVadis Silver Medal
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025